Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 10Recruiting 2No longer available 2Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2

Conditions

Colorectal Neoplasms 13Carcinoma, Hepatocellular 7Neoplasms 3Liver Neoplasms 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Colonic Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Piebaldism 1Patient Compliance 1Pathologic Complete Response 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Multiple Myeloma 1Microsatellite Stable Metastatic Colorectal Cancer 1Meningioma 1Melanoma 1MCRC 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Liver Metastases 1Leiomyosarcoma 1

Interventions

Imatinib Mesylate 8Sunitinib 3ripretinib 2regorafenib 2apatinib 2IDRX-42 2trastuzumab deruxtecan 1pemigatinib 1olverembatinib 1envafolimab 1atezolizumab 1Temozolomide 1Surgical Instruments 1Quality Assurance, Health Care 1Paclitaxel 1Observation 1Neoadjuvant Therapy 1Liquid Biopsy 1Dasatinib 1Blood Specimen Collection 14-Aminopyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Gastrointestinal Stromal Tumors × regorafenib × Clear all
NCT07559864 2026-04-30

Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment

Peking University Cancer Hospital & Institute

Phase 2 Recruiting
100 enrolled
GastrointestinalSarcoma

Piebaldism, Gastrointestinal Stromal Tumors

NCT05366816 2025-09-09

ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

University of Miami

Phase 2 Recruiting
48 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡